A Human ErbB2-Specific T-Cell Receptor Confers Potent Antitumor Effector Functions in Genetically Engineered Primary Cytotoxic Lymphocytes

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Human Gene Therapy

• Publication date

  2014-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/hum.2014.006PMID 25003657PMCID PMC4137348
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enzymatic Discovery of a HER-2/neu Epitope That Generates Cross-Reactive T Cells

  2013influential reference
• Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.

  2013cited by this paper
• A Novel Dendritic Cell-based Immunization Approach for the Induction of Durable Th1-polarized Anti-HER-2/neu Responses in Women With Early Breast Cancer

  2012cited by this paper
• HER2-Positive Breast Cancer

  2012cited by this paper
• Primary Human Ovarian Epithelial Cancer Cells Broadly Express HER2 at Immunologically-Detectable Levels

  2012cited by this paper
• HER-2-Positive Breast Cancer

  2012cited by this paper
• CD3 limits the efficacy of TCR gene therapy in vivo.

  2011cited by this paper
• Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression

  2009cited by this paper
• Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

  2009cited by this paper
• Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR.

  2009cited by this paper
• Molecular Design of the Cαβ Interface Favors Specific Pairing of Introduced TCRαβ in Human T Cells1

  2008cited by this paper
• HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma

  2008cited by this paper
• Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells.

  2008cited by this paper
• CTLs Directed against HER2 Specifically Cross-React with HER3 and HER41

  2008cited by this paper
• Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.

  2007influential reference
• Redirecting T lymphocyte specificity by T cell receptor gene transfer--a new era for immunotherapy.

  2007cited by this paper
• Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.

  2007cited by this paper
• Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability.

  2006cited by this paper
• Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes1

  2006cited by this paper
• Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes

  2006influential reference
• Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.

  2005cited by this paper
• Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR

  2005influential reference
• Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.

  2004cited by this paper
• HER-2, gp100, and MAGE-1 Are Expressed in Human Glioblastoma and Recognized by Cytotoxic T Cells

  2004cited by this paper
• Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.

  2003cited by this paper
• Rapid High Efficiency Sensitization of CD8+ T Cells to Tumor Antigens by Dendritic Cells Leads to Enhanced Functional Avidity and Direct Tumor Recognition Through an IL-12-Dependent Mechanism 1

  2003cited by this paper
• Genetic engineering of T cell specificity for immunotherapy of cancer.

  2003cited by this paper
• Targeting tumours with genetically enhanced T lymphocytes

  2003cited by this paper
• Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.

  2002cited by this paper
• Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells.

  2002cited by this paper
• Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.

  2002cited by this paper
• T-cell-receptor gene therapy

  2002cited by this paper
• Can the Low-Avidity Self-Specific T Cell Repertoire Be Exploited for Tumor Rejection?1

  2002cited by this paper
• Identification of New Epitopes from Four Different Tumor-Associated Antigens: Recognition of Naturally Processed Epitopes Correlates with HLA-A∗0201-Binding Affinity1

  2001cited by this paper
• Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells.

  2000cited by this paper
• Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals.

  2000cited by this paper
• HER‐2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA‐A2.1‐restricted cytotoxic T lymphocytes

  2000cited by this paper
• Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas.

  1999cited by this paper
• Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.

  1998cited by this paper
• Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.

  1998cited by this paper
• Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells.

  1997cited by this paper
• Prevalence and significance of HER-2/neu amplification in epithelial ovarian cancer.

  1995cited by this paper
• Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.

  1995cited by this paper
• Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines.

  1994cited by this paper
• Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.

  1994cited by this paper

• Leveraging epigenetics to enhance the efficacy of cancer-testis antigen: a potential candidate for immunotherapy.

  2022cites this paper
• Comparing the 2017 ASCO/CAP guideline for gastroesophageal adenocarcinoma surgical specimen to the 2018 ASCO/CAP guideline for breast cancer in assessing the HER2 status in primary mucinous ovarian carcinoma

  2022cites this paper
• TCRvβ-CART therapy mediates high-precision targeting of malignant T-cell clones

  2022cites this paper
• Targeting HER2 in breast cancer: new drugs and paradigms on the horizon

  2021cites this paper
• Immunotherapy Advances for Epithelial Ovarian Cancer

  2020cites this paper
• Cellular immunotherapy in breast cancer: The quest for consistent biomarkers.

  2020cites this paper
• Developing neoantigen-targeted T cell–based treatments for solid tumors

  2019cites this paper
• Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches

  2019cites this paper
• Molecular and Cellular Basis of Chemoresistance in Ovarian Cancer

  2019cites this paper
• Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy

  2019cites this paper
• Nature of tumour rejection antigens in ovarian cancer

  2018cites this paper
• T-cell target antigens across major gynecologic cancers.

  2017cites this paper
• Cellules exprimant car dirigées contre de multiples antigènes tumoraux et leurs utilisations

  2016cites this paper
• Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System.

  2016cites this paper
• Tumor infiltrating lymphocytes in ovarian cancer

  2015cites this paper
• CD4+ T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8+ T-cell Targeting of HER2/neu–Expressing Cancers

  2015cites this paper
• Advances and prospects in adoptive cell transfer therapy for ovarian cancer.

  2015cites this paper